ライフサイエンスコーパス: antineutrophil cytoplasmic antibody

1 cerevisiae antibody (ASCA), and perinuclear antineutrophil cytoplasmic antibodies).

2 had a positive test for the myeloperoxidase antineutrophil cytoplasmic antibody.

3 out systemic disease occurs in patients with antineutrophil cytoplasmic antibodies.

4 All but 1 patient had antineutrophil cytoplasmic antibodies (ANCA) against pro

5 Antineutrophil cytoplasmic antibodies (ANCA) are positiv

6 Antineutrophil cytoplasmic antibodies (ANCA) are present

7 ost recent published literature in childhood antineutrophil cytoplasmic antibodies (ANCA) associated

8 Antineutrophil cytoplasmic antibodies (ANCA) binding to

9 Antineutrophil cytoplasmic antibodies (ANCA) directed ag

10 ith Wegener's granulomatosis associated with antineutrophil cytoplasmic antibodies (ANCA) directed ag

11 Antineutrophil cytoplasmic antibodies (ANCA) have been c

12 Two important types of antineutrophil cytoplasmic antibodies (ANCA) have been i

13 n Europe have established the association of antineutrophil cytoplasmic antibodies (ANCA) with vascul

14 Two types of antineutrophil cytoplasmic antibodies (ANCA), antiprotei

15 The pathogenicity of antineutrophil cytoplasmic antibodies (ANCA), however, r

16 rom activation of circulating neutrophils by antineutrophil cytoplasmic antibodies (ANCA), resulting

17 s Wegener's granulomatosis, have circulating antineutrophil cytoplasmic antibodies (ANCA).

18 Patients with myeloperoxidase (MPO) antineutrophil cytoplasmic antibody (ANCA) experience re

19 The increased availability of testing for antineutrophil cytoplasmic antibody (ANCA) has widened t

20 The utility of antineutrophil cytoplasmic antibody (ANCA) levels to gui

21 s to characterize these subgroups further by antineutrophil cytoplasmic antibody (ANCA) pattern and T

22 lness self-management for adults living with antineutrophil cytoplasmic antibody (ANCA)-associated sm

23 and relapse have not been well described in antineutrophil cytoplasmic antibody (ANCA)-associated sm

24 Antineutrophil cytoplasmic antibody (ANCA)-associated va

25 Antineutrophil cytoplasmic antibody (ANCA)-associated va

26 Antineutrophil cytoplasmic antibody (ANCA)-associated va

27 Antineutrophil cytoplasmic antibody (ANCA)-associated va

28 Antineutrophil cytoplasmic antibody (ANCA)-associated va

29 ne of remission-induction therapy for severe antineutrophil cytoplasmic antibody (ANCA)-associated va

30 Current remission maintenance therapies for antineutrophil cytoplasmic antibody (ANCA)-associated va

31 g-term prognosis in two autoimmune diseases, antineutrophil cytoplasmic antibody (ANCA)-associated va

32 Cyclophosphamide induction regimens for antineutrophil cytoplasmic antibody (ANCA)-associated va

33 llowed remissions in relapsing or refractory antineutrophil cytoplasmic antibody (ANCA)-associated va

34 endency to relapse or remain relapse-free in antineutrophil cytoplasmic antibody (ANCA)-associated va

35 Included were patients with active severe antineutrophil cytoplasmic antibody (ANCA)-associated va

36 in patients with severe (organ-threatening) antineutrophil cytoplasmic antibody (ANCA)-associated va

37 RA), systemic lupus erythematosus (SLE), and antineutrophil cytoplasmic antibody (ANCA)-associated va

38 iitis, 16 Churg-Strauss syndrome [CSS]), and antineutrophil cytoplasmic antibody (ANCA)-positive case

39 The triggers that induce antineutrophil cytoplasmic antibody (ANCA)-positive vasc

40 azine, and penicillamine are associated with antineutrophil cytoplasmic antibody (ANCA)-positive vasc

41 Atypical "antineutrophil cytoplasmic antibodies" (ANCA) are presen

42 examines whether exposure of neutrophils to antineutrophil cytoplasmic antibodies (ANCAs) can disrup

43 The development of pathogenic antineutrophil cytoplasmic antibodies (ANCAs) can result

44 the recent advances in understanding of how antineutrophil cytoplasmic antibodies (ANCAs) contribute

45 Antineutrophil cytoplasmic antibodies (ANCAs) have been

46 The clinical significance of antineutrophil cytoplasmic antibodies (ANCAs) in the phe

47 PR3 is the prominent target antigen for antineutrophil cytoplasmic antibodies (ANCAs) in Wegener

48 Antineutrophil cytoplasmic antibodies (ANCAs) target pro

49 Testing for atypical antineutrophil cytoplasmic antibodies (ANCAs) was perfor

50 CSS can be accompanied by antineutrophil cytoplasmic antibodies (ANCAs), but most

51 ti-Saccharomyces cerevisiae, and perinuclear antineutrophil cytoplasmic antibodies and for 3 Crohn's

52 Serological evaluation for antineutrophil cytoplasmic antibodies and human leukocyt

53 Serologic markers such as perinuclear antineutrophil cytoplasmic antibody, anti-Saccharomyces

54 hils that mediates surface expression of the antineutrophil cytoplasmic antibody antigen proteinase 3

55 Antineutrophil cytoplasmic antibodies are a hallmark of

56 Antineutrophil cytoplasmic antibodies are then able to a

57 onset, date of diagnosis, clinical features, antineutrophil cytoplasmic antibody assays, tissue biops

58 nal crisis (SRC), normotensive renal crisis, antineutrophil cytoplasmic antibodies-associated glomeru

59 ed with systemic autoimmune diseases such as antineutrophil cytoplasmic antibodies-associated vasculi

60 a on the outcome of renal transplantation in antineutrophil cytoplasmic antibody-associated glomerulo

61 In contrast, antineutrophil cytoplasmic antibody-associated systemic

62 tion and arterial stiffness in patients with antineutrophil cytoplasmic antibody-associated systemic

63 entral nervous system may be involved in the antineutrophil cytoplasmic antibody-associated systemic

64 induction therapy in refractory or relapsing antineutrophil cytoplasmic antibody-associated vasculiti

65 features in renal biopsies of patients with antineutrophil cytoplasmic antibody-associated vasculiti

66 eased incidence of thromboembolic disease in antineutrophil cytoplasmic antibody-associated vasculiti

67 ted at T cells may improve renal outcomes in antineutrophil cytoplasmic antibody-associated vasculiti

68 uss; EGPA), also collectively referred to as antineutrophil cytoplasmic antibody-associated vasculiti

69 r infection in a cohort of 182 patients with antineutrophil cytoplasmic antibody-associated vasculiti

70 nd proteinase 3 is a major target antigen in antineutrophil cytoplasmic antibody-associated vasculiti

71 d arthritis (RA), Felty's syndrome (FS), and antineutrophil cytoplasmic antibody-associated vasculiti

72 have been implicated in the pathogenesis of antineutrophil cytoplasmic antibody-associated vasculiti

73 oid arthritis, systemic lupus erythematosus, antineutrophil cytoplasmic antibody-associated vasculiti

74 ractice and improve outcome of patients with antineutrophil cytoplasmic antibody-associated vasculiti

75 f health-related quality of life (HRQOL) for antineutrophil cytoplasmic antibody-associated vasculiti

76 Significant advances in the treatment of antineutrophil cytoplasmic antibody-associated vasculiti

77 ed in four distinct cohorts of patients with antineutrophil cytoplasmic antibody-associated vasculiti

78 LE and 11 patients with active or refractory antineutrophil cytoplasmic antibody-associated vasculiti

79 gests that an infectious agent could trigger antineutrophil cytoplasmic antibody-associated vasculiti

80 Cytoplasmic antineutrophil cytoplasmic antibodies (cANCA) that accom

81 patient with chronic, relapsing cytoplasmic antineutrophil cytoplasmic antibody (cANCA)-associated W

82 omyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies cannot yet replace

83 Many of these illnesses are associated with antineutrophil cytoplasmic antibodies (cytoplasmic, peri

84 Antineutrophil cytoplasmic antibodies directed against a

85 Titers of classic antineutrophil cytoplasmic antibodies fell in associatio

86 The recognition of newer antibodies such as antineutrophil cytoplasmic antibody has given us newer c

87 have provided insight into the occurrence of antineutrophil cytoplasmic antibodies in cocaine-induced

88 ay initiate the activation of neutrophils by antineutrophil cytoplasmic antibodies in patients with W

89 se and pachydermoperiostosis associated with antineutrophil cytoplasmic antibodies is described.

90 A circulating antineutrophil cytoplasmic antibody is found in many pat

91 Perinuclear antineutrophil cytoplasmic antibodies lack sensitivity a

92 opathy, antiglomerular basement membrane and antineutrophil cytoplasmic antibody-mediated crescentic

93 Multisystem large vessel vasculitis (antineutrophil cytoplasmic antibody negative) produced a

94 All were antineutrophil cytoplasmic antibody negative.

95 ASCA, outer-membrane porin C/I2, perinuclear antineutrophil cytoplasmic antibodies, or no/low respons

96 ibodies consisting of high-titre perinuclear antineutrophil cytoplasmic antibodies (p-ANCAs) with spe

97 Two probands were antineutrophil cytoplasmic antibody positive vs. 1 of 27

98 seroreactive to I2, and 23% were perinuclear antineutrophil cytoplasmic antibody positive.

99 py and rituximab in a 13-year-old boy with P-antineutrophil cytoplasmic antibody-positive microscopic

100 hange disease, idiopathic membranous GN, and antineutrophil cytoplasmic antibody-positive pauci-immun

101 es of vasculitis, on the other hand, such as antineutrophil cytoplasmic antibody-positive small vesse

102 ained by differing abilities of proteinase 3-antineutrophil cytoplasmic antibody (PR3-ANCA)-positive

103 ing of the underlying pathophysiology of the antineutrophil cytoplasmic antibody-related vasculitides

104 Most patients have a circulating antineutrophil cytoplasmic antibody that appears to be t

105 temic lupus erythematosus, cryoglobulinemia, antineutrophil cytoplasmic antibodies+ vasculitis, and d

106 Perinuclear antineutrophil cytoplasmic antibodies were determined by

107 the treatment of vasculitis associated with antineutrophil cytoplasmic antibodies when standard ther